|
Muscular Dystrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
There is great potential for the use of recombinant human MG53 in treating muscular dystrophy and other diseases in which compromised membrane integrity contributes to the disease.
|
23699904 |
2013 |
|
Muscular Dystrophy
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that systemic delivery and muscle-specific overexpression of human MG53 gene by recombinant adeno-associated virus (AAV) vectors enhanced membrane repair, ameliorated pathology, and improved muscle and heart functions in δ-sarcoglycan (δ-SG)-deficient TO-2 hamsters, an animal model of MD and congestive heart failure.
|
22314291 |
2012 |
|
Muscular Dystrophy
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
No pathogenic MG53 mutations were identified in 50 muscular dystrophy patients, suggesting that MG53 is unlikely to be a common cause of muscular dystrophy in Australia.
|
21412170 |
2011 |
|
Muscular Dystrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our recent studies show that MG53 is essential for muscle membrane repair, and defects in MG53 function are linked to muscular dystrophy and cardiac dysfunction.
|
21343302 |
2011 |
|
Muscular Dystrophy
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.
|
19380584 |
2009 |
|
Metabolic Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
We also measured serum MG53 levels in rodents and humans in the presence or absence of metabolic diseases, particularly T2DM.
|
30586741 |
2019 |
|
Metabolic Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
We will focus on the pathways that MG53 regulates and how the dysregulation of MG53 leads to metabolic disorders, thereby establishing a causal relationship between sustained upregulation of MG53 and the development of muscle insulin resistance and metabolic disorders.
|
29017896 |
2018 |
|
Metabolic Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
It is noteworthy that chronic upregulation of MG53 induces insulin resistance and metabolic diseases, such as type 2 diabetes and its cardiovascular complications, by acting as an E3 ligase to mediate the degradation of insulin receptor and insulin receptor substrate-1.
|
28432201 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, the potential involvement of circulating MG53 in the pathogenesis of T2DM was assessed by neutralizing blood MG53 with monoclonal antibodies in diabetic db/db mice.
|
30586741 |
2019 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Herein, we will review the link between structural and molecular remodelling of the sarcolemma associated with the progression of HF, specifically considering the evidence for: (i) Whether intrinsic, evolutionary conserved, plasma membrane injury-repair mechanisms are in operation in the heart, and (ii) if deficits in key 'wound-healing' proteins (annexins, dysferlin, EHD2 and MG53) may play a yet to be fully appreciated role in triggering sarcolemma microdomain remodelling and/or necrosis.
|
31520263 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Herein, we will review the link between structural and molecular remodelling of the sarcolemma associated with the progression of HF, specifically considering the evidence for: (i) Whether intrinsic, evolutionary conserved, plasma membrane injury-repair mechanisms are in operation in the heart, and (ii) if deficits in key 'wound-healing' proteins (annexins, dysferlin, EHD2 and MG53) may play a yet to be fully appreciated role in triggering sarcolemma microdomain remodelling and/or necrosis.
|
31520263 |
2019 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using perfused rodent hearts or skeletal muscle, we investigated whether high glucose, high insulin, or their combination (conditions mimicking metabolic syndrome or T2DM) alters MG53 protein concentration in the perfusate.
|
30586741 |
2019 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to determine the potential predictive value of TRIM72 immunohistochemical expression in stage II colon carcinoma.
|
30852740 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results indicated that MSC infusion has therapeutic effects in rats and that MG53 in skeletal muscle may be a promising novel therapeutic target protein for MSC‑mediated amelioration of insulin resistance in T2D.
|
29693163 |
2018 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
TRIM72 is involved in insulin resistance and metabolic syndrome, which are risk factors of colon cancer.
|
29806630 |
2018 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Importantly, the lower serum TRIM72 levels were associated with advanced clinical stage, lymph node, and distant metastases in colon cancer patients.
|
29806630 |
2018 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.
|
22314291 |
2012 |
|
Congestive heart failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that systemic delivery and muscle-specific overexpression of human MG53 gene by recombinant adeno-associated virus (AAV) vectors enhanced membrane repair, ameliorated pathology, and improved muscle and heart functions in δ-sarcoglycan (δ-SG)-deficient TO-2 hamsters, an animal model of MD and congestive heart failure.
|
22314291 |
2012 |
|
Myopathy
|
0.020 |
Biomarker
|
group |
BEFREE |
This study explored the expression and localization of MG53 in human skeletal muscle, how membrane repair proteins are modulated in various forms of muscular dystrophy, and whether MG53 is a primary cause of human muscle disease.
|
21412170 |
2011 |
|
Myopathy
|
0.020 |
Biomarker
|
group |
BEFREE |
Upon cell-surface lesion MG53 recruits the vesicles to the repair site in an oxidation-dependent manner and MG53-knockout mice develop progressive myopathy associated with defective membrane repair.
|
19202355 |
2009 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma.
|
30852740 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Second, hyperglycemia is accompanied by increased circulating MG53 in humans and rodents with diabetes mellitus.
|
30586741 |
2019 |
|
Heart valve disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Conclusions Together, our data characterize valve interstitial cell membrane repair as a novel mechanism of protection against valvular remodeling and assess potential in vivo roles of MG 53 in preventing valvular heart disease.
|
30741589 |
2019 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
First, high glucose or high insulin induces MG53 secretion from isolated rodent hearts and skeletal muscle.
|
30586741 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Lack of immunohistochemical expression of TRIM72 in the tumor was significantly and independently associated to recurrence.A recent report by Chen et al. has shown that TRIM72 can be measured in plasma for colon carcinoma detection as an alternative to CEA or CA19.9, with lower levels in patients with carcinoma.
|
30852740 |
2019 |